The SELECT, LEADER, and SUSTAIN-6 trials established GLP-1 agonists as cardiovascular medicines with mortality-reducing evidence. Here is what that evidence means for longevity medicine.
The SELECT, LEADER, and SUSTAIN-6 trials established GLP-1 agonists as cardiovascular medicines with mortality-reducing evidence. Here is what that evidence means for longevity medicine.
This profile synthesizes the published human evidence. The evidence tier system — Strong, Moderate, Emerging, Insufficient — is based on published peer-reviewed data only, with hard longevity outcomes weighted more heavily than surrogate endpoints. The full profile with all indexed papers and active trial alerts is available to subscribers.
Evidence tier: Strong. The case for clinical consideration rests on the mechanistic coherence and the published surrogate-endpoint human trial signal. The case for caution rests on the absence of hard longevity outcome data in adequately powered trials.
A physician discussing this intervention with a patient should communicate the evidence tier honestly and distinguish between what has been shown in published trials versus what is claimed in supplement marketing. The full Geroevidence profile includes the specific papers, effect sizes, and confidence intervals that inform this assessment.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.